BioCentury
ARTICLE | Product Development

On SLE's trail

What MedImmune is doing to increase odds of Phase III SLE success for anifrolumab

November 16, 2015 8:00 AM UTC

AstraZeneca plc's MedImmune LLC unit is following a clinical development trail for lupus candidate anifrolumab first blazed by Benlysta belimumab. The company hopes that its track record of successful mid-stage trials in the indication have set it up to confirm anifrolumab's Phase II higher response rates in an ongoing Phase III.

MedImmune presented Phase II results last week showing a placebo-adjusted response rate of 22.4% at 365 days for the dose now in Phase III, outperforming the 14% placebo-adjusted response rate on Benlysta's label and the 12.3% rates GlaxoSmithKline plc reported for a subcutaneous formulation of the drug...